GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (FRA:83B) » Definitions » Valuation Rank

3SBio (FRA:83B) Valuation Rank


View and export this data going back to 2015. Start your Free Trial

What is 3SBio Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

3SBio Valuation Rank Related Terms

Thank you for viewing the detailed overview of 3SBio's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

3SBio (FRA:83B) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (FRA:83B) » Definitions » Valuation Rank
Comparable Companies
HKSE:06826 HKSE:06990 HKSE:02162 HKSE:09688 HKSE:09969 HKSE:01541 HKSE:06660 HKSE:09966 HKSE:01952 HKSE:02315 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
01530:Hong Kong 83B:Germany
Address
No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027
Website
https://www.3sbio.com
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.